Addition of Fluoroquinolone Prophylaxis to a Blood and Marrow Transplant Unit to Reduce Gram-Negative Infections

Karam G.H. , Dunn D.L. , Graybill J.R. . Emerging Resistance in Bacteria and Fungus: A Global Problem. Presented at the Medical Education Collaborative Symposium Proceedings, 2000; Golden, Colo.

Fridkin S.K. , Steward C.D. , Edwards J.R. . Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis. 1999; 29: 245–252.

Swartz M.N. . Use of antimicrobial agents and drug resistance. N Engl J Med. 1997; 337: 491–492.

Giamarellou H. , Antoniadou A. . Infectious complications of febrile leukopenia. Infect Dis Clin North Am. 2001; 15: 457–482.

Ponce-de-Leon A. , Lopez-Meneses M. , Sifuentes-Osornio J. . Cefepime versus ceftazidime for the treatment of serious bacterial infections. Diagn Microbiol Infect Dis. 1999; 5: 263–268.

Chatzinikolaou I. , Abi-Said D. , Bokey G. . Recent experience with pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med. 2000; 160: 501–509.

Poutsiaka D.D. . Antimicrobial resistance in the chronically critically ill patient. Clin Chest Med. 2001; 22: 87–103.

Jones R.N. . Resistance patterns among nosocomial pathogens: trends over the past few years. Chest. 2001; 119 (2 suppl): 397S–404S.

Leather H.L. , Wingard J.R. . Infections following hematopoietic stem cell transplantation. Infect Dis Clin North Am. 2001; 15: 483–520.

Giamarellou H. , Antoniadou A. . Antipseudomonal antibiotics. Med Clin North Am. 2001; 85: 19–42.

Boswell F.J. , Wise R. . Advances in the macrolides and quinolones. Infect Dis Clin North Am. 1998; 12: 647–670.

Chandrasekar P.H. , Arnow P.M. . Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Ann Pharmacother. 2000; 34: 989–995.

Wang F.D. , Liu C.Y. , Hsu H.C. . A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. Chemotherapy. 1999; 45: 370–379.

Kebudi R. , Gorgun O. , Ayan I. . Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol. 2001; 36: 434–441.

Hancock R.E.W. . Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentive gram-negative bacteria. Clin Infect Dis. 1998; 27(Suppl 1): 93–S99.

Gales A.C. , Jones R.N. , Turnidge J. . Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001; 32(Suppl 2): S146–S155.

Winokur P.L. , Canton R. , Casellas J.M. . Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis. 2001; 32(Suppl 2): S94–S103.

de Man P. , van Der Veeke E. , Leemreijze M. . Enterobacter species in a pediatric hospital: horizontal transfer or selection in individual patients? J Infect Dis. 2001; 184: 211–214.

Nordmann P. . Trends in beta-lactam resistance among Enterobacteriaceae. Clin Infect Dis. 1998; 27(Suppl 1): S100–S106.

Then R.L. , Angehrn P. . Trapping of nonhydrolyzable cephalosporins by cephalosporinases in Enterobacter cloacae and Pseudomonas aeruginosa as a possible resistance mechanism. Antimicrob Agents Chemother. 1982; 21: 711–717.

Carratala J. , Fernandez-Sevilla A. , Tubau F. . Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995; 20: 557–563.